NCT00436449已完成2 期
A Double Blind, Within Subject, Placebo Controlled Randomised Trial to Investigate the Scar Improvement Efficacy of a Single Intradermal Application of RN1001 (Avotermin) in Female Subjects Undergoing Bilateral Breast Augmentation
Renovo14 个研究点 分布在 1 个国家目标入组 63 人开始时间: 2004年12月1日最近更新:
适应症
相关药物
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 发起方
- 入组人数
- 63
- 试验地点
- 14
- 主要终点
- Patient scar assessment
研究概览
简要总结
This will be a multi-centre, double-blind, within-subject, placebo controlled randomised trial in female subjects. All subjects will undergo bilateral breast augmentation surgery. Immediately following surgery, each subject will receive 100µl containing 50ng or 200ng of RN1001 per linear centimetre intradermally into both margins of one breast wound, and 100µl of placebo solution per linear centimetre intradermally into both margins of their other breast wound. The allocation of treatment to wound (left or right) will be randomised and double blind.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Prevention
- 盲法
- Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
入排标准
- 年龄范围
- 18 Years 至 60 Years（Adult）
- 性别
- Female
- 接受健康志愿者
- 否
入选标准
- •Female subjects between 18 and 60 years of age undergoing bilateral breast augmentation through an infra-mammary fold incision who have given written informed consent.
- •Weight between 50 and 150kg and a body mass index within the permitted range for their height using Quetelet's index-weight (kg)/height²(m). The permitted index is between 15-
- •Subjects of child bearing potential who are using method(s) of contraception acceptable to the Investigator and agree to do so from at least the screening visit until 1 month post surgery.
- •Subjects where the same implant position will be used for each breast; the implants can be placed in sub-mammary or sub-pectoral pockets.
- •Subjects where the same type and size of implant is to be used for each breast.
- •Subjects with, in the opinion of the Investigator, clinically acceptable results for the laboratory tests specified in the trial protocol . All laboratory tests must be performed within 28 days prior to Day 0.
排除标准
- •Subjects with significant breast asymmetry where this may produce a different length or site of wound, or where there will be a different post-operative tension on the wound.
- •Subjects who on direct questioning and physical examination have a history or evidence of hypertrophic or keloid scarring.
- •Subjects who have had surgery in the area to be incised within one year of Day
- •Subjects with a personal history of a bleeding disorder.
- •Subjects with any history of breast malignancy.
- •Subjects with a skin disorder that is chronic or currently active and which the Investigator considers will adversely affect the healing of the acute wounds or involves the areas to be examined in this trial.
- •Subjects who on direct questioning and/or physical examination, have evidence of any past or present clinically significant medical condition that would impair wound healing.
- •Subjects with a history of clinically significant hypersensitivity to any of the drugs or surgical dressings to be used in this trial.
- •Subjects who are taking, or have taken, any investigational drugs including RN1001 within 3 months prior to the screening visit.
- •Subjects who are taking regular, continuous, oral corticosteroid therapy.
- •Subjects undergoing investigations or changes in management for an existing medical condition.
- •Subjects who are or who become pregnant up to and including Day 0 or who are lactating.
- •Subjects with diseases or conditions that could in the opinion of the Investigator interfere with the assessment of safety, tolerability and efficacy.
- •In the opinion of the Investigator, a subject who is not likely to complete the trial for what ever reason.
结局指标
主要结局
Patient scar assessment
Investigator scar assessment
Independent scar assessment
次要结局
- Local tolerance
- Adverse events
研究者
研究点 (14)
Loading locations...
相似试验
已完成
2 期
A Trial of a Botanical Drug (EISO) for Treatment of Mild-to-Moderate Plaque PsoriasisPlaque PsoriasisNCT03000608Santalis Pharmaceuticals, Inc.69
已完成
4 期
Assess the Efficacy, Safety and Tolerability of Gefitinib (Iressa® 250mg) as Maintenance Therapy in Locally Advanced or Metastatic (Stage IIIB/IV) Non Small Cell Lung Cancer (NSCLC)Non-small Cell Lung Cancer (NSCLC)NCT00770588AstraZeneca296
Unknown
4 期
A Clinical Study to Evaluate the Efficacy and Safety of Hemocoagulase InjectionHemoptysisNCT03270735Lee's Pharmaceutical Limited100
已完成
2 期
Double-Blind,Randomized,Placebo-Controlled Efficacy & Safety Study of EUFLEXXA™ for Treatment of OA of the First CMCOsteoarthritisNCT00423371Ferring Pharmaceuticals79
Unknown
2 期
Hepar-P Study to Evaluate the Safety and Efficacy of a Standardised Extract of Phyllanthus Niruri for the Treatment of Non-alcoholic Fatty Liver DiseaseNon-alcoholic Fatty Liver DiseaseNCT01680003Nova Laboratories Sdn Bhd50